Goods & Services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Goods & Services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Goods & Services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Abstract

The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: Wherein R1, L1, R2, L2, R3, Cy, and the subscript n are as defined herein. The present invention discloses compounds according to Formula I: Wherein R1, L1, R2, L2, R3, Cy, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IFNα, IL12 and/or IL23 by administering the compound of the invention.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/5355 - Non-condensed oxazines containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07D 471/04 - Ortho-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

11, R1 and Cy are as defined herein. Herein are disclosed compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving tuberculosis (TB) and/or non-tuberculous mycobacteria (NTM).

IPC Classes  ?

• A61P 31/04 - Antibacterial agents
• A61P 31/06 - Antibacterial agents for tuberculosis
• C07D 498/10 - Spiro-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

Herein is provided inter alia, CD20-binding domains and chimeric antigen receptors (CARs), as well as corresponding nucleic acid molecules, vectors, cells, compositions, methods and uses, which are particularly useful in the prevention and/or treatment of cancer and/or autoimmune disease.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/42 - Cancer antigens
• C07K 14/725 - T-cell receptors

Abstract

11, R1 and Cy are as defined herein. Herein are disclosed compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving tuberculosis (TB) and/or non-tuberculous mycobacteria (NTM).

IPC Classes  ?

• A61P 31/06 - Antibacterial agents for tuberculosis
• A61P 31/10 - Antimycotics
• C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems

Goods & Services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; Pharmaceutical drug development services Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others

Goods & Services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; Pharmaceutical drug development services Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others

Goods & Services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; Pharmaceutical drug development services Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others

Goods & Services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Goods & Services

(1) Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. (1) Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; pharmaceutical drug development services. (2) Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Abstract

The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: wherein R1, R2a, R2b, R3, X, Y, and the subscript n are as defined herein. The present invention discloses compounds according to Formula I: wherein R1, R2a, R2b, R3, X, Y, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving neurodegenerative disorders by administering the compound of the invention.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Goods & Services

Pharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, cancer, hematological cancer, solid tumors, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, dermatomyositis, urticaria, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes; biopharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, cancer, hematological cancer, solid tumors, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, dermatomyositis, urticaria, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes Medical and scientific research services; industrial research in the field of pharmaceuticals; pharmaceutical and biopharmaceutical research and development services; scientific and medical research services in the nature of examining and testing of genes; pharmaceutical and biopharmaceutical drug development services featuring the, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; pharmaceutical drug development services featuring the, examination and testing of medicaments; product research and development in the field of test systems for pharmaceutical and biopharmaceutical products; database development services, namely, configuration and customization of computer databases containing information regarding medical, pharmaceutical and biopharmaceutical information; pharmaceutical drug development services Medical services; Medical advisory services; Medical and pharmaceutical consultation; Pharmaceutical advice

Abstract

The present invention discloses compounds according to Formula (I), wherein G and Cy are as defined herein. Herein are disclosed compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving tuberculosis (TB) and/or non-tuberculous mycobacteria (NTM).

IPC Classes  ?

• C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61P 31/06 - Antibacterial agents for tuberculosis
• A61P 31/10 - Antimycotics
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems

Abstract

11, R1, R2, R3, R4a, R4b, R5, R6, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of proliferative diseases by administering a compound of the invention.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07D 213/40 - Acylated substituent nitrogen atom
• C07D 213/53 - Nitrogen atoms
• C07D 213/55 - AcidsEsters
• C07D 213/56 - Amides
• C07D 213/57 - Nitriles
• C07D 213/64 - One oxygen atom attached in position 2 or 6
• C07D 213/73 - Unsubstituted amino or imino radicals
• C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
• C07D 237/08 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 405/10 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 411/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 411/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 471/14 - Ortho-condensed systems
• C07D 498/04 - Ortho-condensed systems

Abstract

122, R1, and R2 are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12, IL-17 and/or IL-23, respiratory diseases, endocrine diseases, metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering a compound of the invention.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

The present invention discloses compounds according to Formula (I), wherein R1, R2, R3, R4, R5, R6a, R6b, R6c, R6d, R7, R8, R9and R10 are as defined herein. The present invention relates to compounds having α4β7 integrin inhibitory action, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of a disease, disorder or condition that is mediated by α4β7 integrin, by administering the compound of the invention.

IPC Classes  ?

• C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
• C07D 213/84 - Nitriles
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 213/643 - 2-PhenoxypyridinesDerivatives thereof
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone

IPC Classes  ?

• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61P 17/06 - Antipsoriatics
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• C07D 471/04 - Ortho-condensed systems

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• C07D 471/04 - Ortho-condensed systems

Abstract

Herein are provided, inter alia, novel compositions and solid forms of compound (I) useful in the prophylaxis and/or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IFNα, interferons ("interferonopathies", especially type I or type III interferonopathies), IL-12 and/or IL-23.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61P 17/06 - Antipsoriatics
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention provides compounds according to Formula (I), wherein R1, R21233 are as defined herein. The present invention also provides methods for the production of such compounds, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IFNα, IL-12 and/or IL-23 by administering the compounds of the invention.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention relates to improved methods for the use of a compound according to formula I in the treatment of fibrosis, in particular idiopathic pulmonary fibrosis (IPF), by contraindicating combined therapy with specific IPF therapeutic compounds, where the combined therapy results in a poorer adverse event profile. The present invention relates to improved methods for the use of a compound according to formula I in the treatment of fibrosis, in particular idiopathic pulmonary fibrosis (IPF), by contraindicating combined therapy with specific IPF therapeutic compounds, where the combined therapy results in a poorer adverse event profile.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61P 11/00 - Drugs for disorders of the respiratory system

Goods & Services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Goods & Services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; Pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Goods & Services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Abstract

The present invention discloses compounds according to Formula (I) wherein R1, R2a, R2b, R3, X, Y, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving neurodegenerative disorders by administering the compound of the invention.

IPC Classes  ?

• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 471/04 - Ortho-condensed systems

Abstract

The present invention discloses compounds according to Formula (I) wherein R1, R2a, R2b, R3, X, Y, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving neurodegenerative disorders by administering the compound of the invention.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Goods & Services

Pharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, autoinflammation diseases, autoimmune diseases, proliferative diseases, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes; Biopharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, autoinflammation diseases, autoimmune diseases, proliferative diseases, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes Medical, scientific and industrial research services; industrial research in the field of pharmaceuticals; pharmaceutical and biopharmaceutical research and development services; scientific and medical research services in the nature of examining and testing of genes; pharmaceutical and biopharmaceutical drug development services featuring the examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; pharmaceutical drug development services featuring the examination and testing of medicaments; product research and development in the field of test systems for pharmaceutical and biopharmaceutical products; database development services , namely configuration and customization of computer databases containing information regarding medical, pharmaceutical and biopharmaceutical information; Pharmaceutical drug development services Medical services; providing medical and pharmaceutical advice; gene bank services

Goods & Services

Pharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, autoinflammation diseases, autoimmune diseases, proliferative diseases, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes; Biopharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, autoinflammation diseases, autoimmune diseases, proliferative diseases, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes Medical, scientific and industrial research services; industrial research in the field of pharmaceuticals; pharmaceutical and biopharmaceutical research and development services; scientific and medical research services in the nature of examining and testing of genes; pharmaceutical and biopharmaceutical drug development services featuring the examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; pharmaceutical drug development services featuring the examination and testing of medicaments; product research and development in the field of test systems for pharmaceutical and biopharmaceutical products; database development services, namely configuration and customization of computer databases containing information regarding medical, pharmaceutical and biopharmaceutical information; Pharmaceutical drug development services Medical services; providing medical and pharmaceutical advice; gene bank services

Goods & Services

Pharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, autoinflammation diseases, autoimmune diseases, proliferative diseases, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes; Biopharmaceutical substances and preparations for human use for the treatment of bone cartilage and joint disease, autoinflammation diseases, autoimmune diseases, proliferative diseases, endocrine diseases, metabolic diseases, skin diseases, lung diseases, fibrotic diseases, cardiovascular diseases, pain, hepatitis B virus, kidney diseases, osteoporosis, osteoarthritis, rheumatoid arthritis, atopic dermatitis, idiopathic pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, Sjogren's syndrome, lupus, uveitis, scleroderma, non-alcoholic steatohepatitis, polycystic kidney disease, type 2 diabetes Medical, scientific and industrial research services; industrial research in the field of pharmaceuticals; pharmaceutical and biopharmaceutical research and development services; scientific and medical research services in the nature of examining and testing of genes; pharmaceutical and biopharmaceutical drug development services featuring the examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; pharmaceutical drug development services featuring the examination and testing of medicaments; product research and development in the field of test systems for pharmaceutical and biopharmaceutical products; database development services, namely configuration and customization of computer databases containing information regarding medical, pharmaceutical and biopharmaceutical information; Pharmaceutical drug development services Medical services; providing medical and pharmaceutical advice; gene bank services

Abstract

The present invention relates to improved methods for the use of the compound according to Formula (I) in the treatment of inflammatory diseases, and/or diseases associated with hypersecretion of INFα and/or interferons ("interferonopathies", especially type I interferonopathies), IL-12 and/or IL-23, avoiding, contraindicating or discontinuing concomitant use or co-administration of one or more compounds that are cytochrome P450 (CYP) inhibitors and/or P-gp inhibitors, particularly CYP3A4 inhibitors and/or P-gp inhibitors, and more particularly strong CYP3A4 inhibitors and/or strong P-gp inhibitors.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 17/00 - Drugs for dermatological disorders
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 37/02 - Immunomodulators
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention relates to improved methods for the use of the compound according to Formula (I) in the treatment of inflammatory diseases, and/or diseases associated with hypersecretion of INFα and/or interferons ("interferonopathies", especially type I interferonopathies), IL-12 and/or IL-23, avoiding, contraindicating or discontinuing concomitant use or co-administration of one or more compounds that are cytochrome P450 (CYP) inducers and/or P-gp inducers, particularly CYP3A4 inducers and/or P-gp inducers, and more particularly strong CYP3A4 inducers and/or strong P-gp inducers.

IPC Classes  ?

• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention relates to substantially pure Clarithromycin 9-oxime more particularly Clarithromycin 9(E)-oxime having purity more than 98% and corresponding (Z)-isomer not more than 1%. The present invention further relates to a process for preparation of Clarithromycin 9(E)-oxime of formula (I), its pharmaceutically acceptable salts and purification. The present invention relates to substantially pure Clarithromycin 9-oxime more particularly Clarithromycin 9(E)-oxime having purity more than 98% and corresponding (Z)-isomer not more than 1%. The present invention further relates to a process for preparation of Clarithromycin 9(E)-oxime of formula (I), its pharmaceutically acceptable salts and purification.

IPC Classes  ?

• C07H 17/08 - Hetero rings containing eight or more ring members, e.g. erythromycins
• C07H 1/00 - Processes for the preparation of sugar derivatives

Goods & Services

Pharmaceutical substances and preparations for human use; Biopharmaceutical substances and preparations for human use.. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; the examination and testing of genes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; Pharmaceutical drug development services.. Medical services; Medical and pharmaceutical advisory and consultancy services; Preparing pharmaceuticals for others..

Goods & Services

Pharmaceutical substances and preparations for human use; Biopharmaceutical substances and preparations for human use.. Medical, scientific and industrial research services; Pharmaceutical and biopharmaceutical research and development services; The examination and testing of genes; Development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; Development, examination and testing of medicaments; The development of test systems for pharmaceutical and biopharmaceutical products; Development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; Pharmaceutical drug development services.. Medical services; Medical and pharmaceutical advisory and consultancy services; Preparing pharmaceuticals for others..

Goods & Services

Pharmaceutical substances and preparations for human use; Biopharmaceutical substances and preparations for human use.. Medical, scientific and industrial research services; Pharmaceutical and biopharmaceutical research and development services; The examination and testing of genes; Development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; Development, examination and testing of medicaments; The development of test systems for pharmaceutical and biopharmaceutical products; Development of databases in the medical, pharmaceutical and biopharmaceutical field and development of gene banks; Pharmaceutical drug development services.. Medical services; Medical and pharmaceutical advisory and consultancy services; Preparing pharmaceuticals for others..

Goods & Services

Software used as medical monitoring and control tool; software as a medical device [SaMD]; computer software for use in medical decision support systems. Medical apparatus and instruments; apparatus and instruments for cell analysis for medical use; medical apparatus and instrument in the form of a system comprising an automated manufacturing device incorporated with reagents and software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment. Software as a service (SaaS) featuring software for medical monitoring and control; providing non-downloadable, cloud-based software featuring software for medical monitoring and control; software as a service for use in medical decision support systems; providing non-downloadable, cloud-based software featuring software for use in medical decision support systems; providing information about the results of clinical trials for pharmaceutical products; conducting clinical trials; providing information about the results of clinical trials; evaluation pharmaceutical products; providing information regarding the evaluation of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical (product) evaluation services. Medical services; medical and pharmaceutical (product) advisory and consultancy services; cell therapy services; medical services relating to the removal, treatment and processing of human cells.

Goods & Services

Software used as medical monitoring and control tool; software as a medical device [samd]; computer software for use in medical decision support systems. Medical apparatus and instruments; apparatus and instruments for cell analysis for medical use; medical apparatus and instrument in the form of a system comprising an automated manufacturing device incorporated with reagents and software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment. Software as a service (saas) featuring software for medical monitoring and control; providing non-downloadable, cloud-based software featuring software for medical monitoring and control; software as a service for use in medical decision support systems; providing non-downloadable, cloud-based software featuring software for use in medical decision support systems; providing information about the results of clinical trials for pharmaceutical products; conducting clinical trials; providing information about the results of clinical trials; evaluation of pharmaceutical products; providing information regarding the evaluation of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical (product) evaluation. Medical services; medical and pharmaceutical (product) advisory and consultancy services; cell therapy services; medical services relating to the removal, treatment and processing of human cells.

Goods & Services

Software used as medical monitoring and control tool; software as a medical device [samd]; computer software for use in medical decision support systems. Medical apparatus and instruments; apparatus and instruments for cell analysis for medical use; medical apparatus and instrument in the form of a system comprising an automated manufacturing device incorporated with reagents and software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment. Software as a service (saas) featuring software for medical monitoring and control; providing non-downloadable, cloud-based software featuring software for medical monitoring and control; software as a service for use in medical decision support systems; providing non-downloadable, cloud-based software featuring software for use in medical decision support systems; providing information about the results of clinical trials for pharmaceutical products; conducting clinical trials; providing information about the results of clinical trials; evaluation of pharmaceutical products; providing information regarding the evaluation of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical (product) evaluation. Medical services; medical and pharmaceutical (product) advisory and consultancy services; cell therapy services; medical services relating to the removal, treatment and processing of human cells.

Goods & Services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use; clinical diagnostic reagents. Education services, namely, organizing and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals; provision of training, namely provision of training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; laboratory analysis and testing services in the field of gene expression; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of computer databanks containing information concerning gene expression and gene therapy; pharmaceutical drug development services; conducting clinical trials; providing information about the results of clinical trials for pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others; stemcell and celltherapy services; medical services relating to the removal, treatment and processing of human cells.

Goods & Services

Pharmaceutical substances and preparations for human use, namely, pharmaceutical preparations and engineered patient T cells for the treatment of cancer; biopharmaceutical substances and preparations for human use, namely, biopharmaceutical preparations and engineered patient T cells for the treatment of cancer; clinical diagnostic reagents for medical use Education services, namely, organizing and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals; provision of training, namely, provision of training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals Medical, scientific and industrial research services in the field of pharmaceuticals, engineered patient T-cells, cell therapy, and gene therapy; pharmaceutical and biopharmaceutical research and development services; laboratory analysis and testing services in the field of gene expression, namely, analysis and testing of cells to determine the presence of particular genes; analysis and testing of cells to determine efficacy for treatment of cancer; development, examination, namely, quality control, and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis and testing of medicaments; development of test systems in the nature of testing procedures and protocols, computer software for testing, reagents and testing kits for testing for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of computer databanks containing information concerning gene expression and gene therapy; pharmaceutical drug development services; scientific research in the nature of conducting clinical trials for others; Providing information about the results of clinical trials for pharmaceutical products; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others being engineered patient T-cells; medical services, namely, Stemcell and celltherapy services; Medical services relating to the removal, treatment and processing of human cells

Abstract

The present invention relates to new and improved methods for the use of Compound 1 in the treatment of inflammatory diseases and/or diseases associated with hypersecretion of IFNa and/or interferons ("interferonopathies", especially type I interferonopathies), IL-12 and/or IL-23, and pharmaceutical unit dosage compositions comprising compound 1 for use therein.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 17/00 - Drugs for dermatological disorders
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 37/02 - Immunomodulators
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

The present invention relates to new and improved methods for the use of Compound 1 in the treatment of inflammatory diseases and/or diseases associated with hypersecretion of IFNa and/or interferons ("interferonopathies", especially type I interferonopathies), IL-12 and/or IL-23, and pharmaceutical unit dosage compositions comprising compound 1 for use therein.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 17/00 - Drugs for dermatological disorders
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 37/02 - Immunomodulators
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Goods & Services

recorded software used as medical monitoring and control tool, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; recorded software as a medical device (SaMD), specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; recorded computer software for use in medical decision support systems specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment Medical apparatus and instruments for use in apheresis, production of cell and gene therapies, testing, analysis, and quality assurance of cell and gene therapies, infusion of cell and gene therapies, and analysis of data gathered from the cell and gene therapy treatment; apparatus and instruments for cell analysis for medical use, namely, cancer and autoimmune disease treatment; medical apparatus in the nature of a system comprising an automated manufacturing device, reagents, software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment Software as a service (SAAS) services featuring software for medical monitoring and control specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; providing temporary use of nondownloadable, cloud-based software featuring software for medical monitoring and control specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; software as a service (SAAS) services for use in medical decision support systems, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment; providing temporary use of non-downloadable, cloud-based software featuring software for use in medical decision support systems, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment; Providing information about the results of clinical trials for pharmaceutical products; scientific research in the nature of conducting clinical trials; Providing information about the results of clinical trials; evaluation pharmaceutical products in the nature of product quality testing; providing information regarding the product quality testing and clinical trials of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical product quality testing; advisory and consultancy services in the field of medical and pharmaceutical product development Medical services; medical and pharmaceutical evaluation of medical and pharmaceutical products to determine effectiveness and suitability for use in treatment of specific medical conditions; medical services, namely, cell therapy services; Medical services relating to the removal, treatment and processing of human cells

Goods & Services

recorded software used as medical monitoring and control tool, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; recorded software as a medical device (SaMD), specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; recorded computer software for use in medical decision support systems specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment Medical apparatus and instruments for use in apheresis, production of cell and gene therapies, testing, analysis, and quality assurance of cell and gene therapies, infusion of cell and gene therapies, and analysis of data gathered from the cell and gene therapy treatment; apparatus and instruments for cell analysis for medical use, namely, cancer and autoimmune disease treatment; medical apparatus in the nature of a system comprising an automated manufacturing device, reagents, software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment Software as a service (SAAS) services featuring software for medical monitoring and control specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; providing temporary use of nondownloadable, cloud-based software featuring software for medical monitoring and control specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; software as a service (SAAS) services for use in medical decision support systems, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment; providing temporary use of non-downloadable, cloud-based software featuring software for use in medical decision support systems, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment; Providing information about the results of clinical trials for pharmaceutical products; scientific research in the nature of conducting clinical trials; Providing information about the results of clinical trials; evaluation pharmaceutical products in the nature of product quality testing; providing information regarding the product quality testing and clinical trials of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical product quality testing; advisory and consultancy services in the field of medical and pharmaceutical product development Medical services; medical and pharmaceutical evaluation of medical and pharmaceutical products to determine effectiveness and suitability for use in treatment of specific medical conditions; medical services, namely, cell therapy services; Medical services relating to the removal, treatment and processing of human cells

Goods & Services

recorded software used as medical monitoring and control tool, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; recorded software as a medical device (SaMD), specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; recorded computer software for use in medical decision support systems specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment Medical apparatus and instruments for use in apheresis, production of cell and gene therapies, testing, analysis, and quality assurance of cell and gene therapies, infusion of cell and gene therapies, and analysis of data gathered from the cell and gene therapy treatment; apparatus and instruments for cell analysis for medical use, namely, cancer and autoimmune disease treatment; medical apparatus in the nature of a system comprising an automated manufacturing device, reagents, software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment Software as a service (SAAS) services featuring software for medical monitoring and control specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; providing temporary use of nondownloadable, cloud-based software featuring software for medical monitoring and control specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; software as a service (SAAS) services for use in medical decision support systems, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment; providing temporary use of non-downloadable, cloud-based software featuring software for use in medical decision support systems, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment; Providing information about the results of clinical trials for pharmaceutical products; scientific research in the nature of conducting clinical trials; Providing information about the results of clinical trials; evaluation pharmaceutical products in the nature of product quality testing; providing information regarding the product quality testing and clinical trials of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical product quality testing; advisory and consultancy services in the field of medical and pharmaceutical product development Medical services; medical and pharmaceutical evaluation of medical and pharmaceutical products to determine effectiveness and suitability for use in treatment of specific medical conditions; medical services, namely, cell therapy services; Medical services relating to the removal, treatment and processing of human cells

Goods & Services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use; clinical diagnostic reagents. Education services, namely, organizing and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals; provision of training, namely provision of training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; laboratory analysis and testing services in the field of gene expression; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of computer databanks containing information concerning gene expression and gene therapy; pharmaceutical drug development services; conducting clinical trials; Providing information about the results of clinical trials for pharmaceutical products; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others; Stemcell and celltherapy services; Medical services relating to the removal, treatment and processing of human cells.

Goods & Services

Software used as medical monitoring and control tool; Software as a medical device [SaMD]; Computer software for use in medical decision support systems. Medical apparatus and instruments; apparatus and instruments for cell analysis for medical use; a system comprising an automated manufacturing device, reagents, software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment. Software as a service (Saas) featuring software for medical monitoring and control; non-downloadable, cloud-based software featuring software for medical monitoring and control; software as a service for use in medical decision support systems; non-downloadable, cloud-based software featuring software for use in medical decision support systems; Providing information about the results of clinical trials for pharmaceutical products; conducting clinical trials; Providing information about the results of clinical trials; evaluation pharmaceutical products; providing information regarding the evaluation of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical services; medical and pharmaceutical (product) evaluation, advisory and consultancy services; cell therapy services; Medical services relating to the removal, treatment and processing of human cells.

Goods & Services

Software used as medical monitoring and control tool; Software as a medical device [SaMD]; Computer software for use in medical decision support systems. Medical apparatus and instruments; apparatus and instruments for cell analysis for medical use; a system comprising an automated manufacturing device, reagents, software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment. Software as a service (Saas) featuring software for medical monitoring and control; non-downloadable, cloud-based software featuring software for medical monitoring and control; software as a service for use in medical decision support systems; nondownloadable, cloud-based software featuring software for use in medical decision support systems; Providing information about the results of clinical trials for pharmaceutical products; conducting clinical trials; Providing information about the results of clinical trials; evaluation pharmaceutical products; providing information regarding the evaluation of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical services; medical and pharmaceutical (product) evaluation, advisory and consultancy services; cell therapy services; Medical services relating to the removal, treatment and processing of human cells.

Goods & Services

Software used as medical monitoring and control tool; Software as a medical device [SaMD]; Computer software for use in medical decision support systems. Medical apparatus and instruments; apparatus and instruments for cell analysis for medical use; a system comprising an automated manufacturing device, reagents, software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment. Software as a service (Saas) featuring software for medical monitoring and control; non-downloadable, cloud-based software featuring software for medical monitoring and control; software as a service for use in medical decision support systems; non-downloadable, cloud-based software featuring software for use in medical decision support systems; Providing information about the results of clinical trials for pharmaceutical products; conducting clinical trials; Providing information about the results of clinical trials; evaluation pharmaceutical products; providing information regarding the evaluation of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical services; medical and pharmaceutical (product) evaluation, advisory and consultancy services; cell therapy services; Medical services relating to the removal, treatment and processing of human cells.

Abstract

The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: Wherein R1, R2, and Cy are as defined herein. The present invention discloses compounds according to Formula I: Wherein R1, R2, and Cy are as defined herein. The present invention relates to compounds, methods for the production of said compounds, pharmaceutical compositions comprising said compounds and methods for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases, pain, fibrosis and/or proliferative diseases by administering said compounds.

IPC Classes  ?

• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• C07D 471/04 - Ortho-condensed systems
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

The present invention relates to prodrug compounds and their use in the treatment of Cystic Fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

IPC Classes  ?

• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: Wherein R1, R2, R5 and Cy are as defined herein. The present invention discloses compounds according to Formula I: Wherein R1, R2, R5 and Cy are as defined herein. The present invention relates to compounds, methods for the production of said compounds, pharmaceutical compositions comprising said compounds and methods for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases, pain, fibrosis and/or proliferative diseases by administering said compounds.

IPC Classes  ?

• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07D 471/04 - Ortho-condensed systems

Abstract

The present invention relates to solid forms of (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione and to pharmaceutical preparations comprising them and methods of their manufacture, as well as the use of said solid forms or preparations for the prophylaxis and/or treatment of inflammatory conditions, muscular disease, fibrotic diseases, viral infection, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis, especially osteoarthritis.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 19/00 - Drugs for skeletal disorders
• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: Wherein R1, R2, R5 and Cy are as defined herein. The present invention discloses compounds according to Formula I: Wherein R1, R2, R5 and Cy are as defined herein. The present invention relates to compounds, methods for the production of said compounds, pharmaceutical compositions comprising said compounds and methods for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases, pain, fibrosis and/or proliferative diseases by administering said compounds.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to solid forms of (5S)-cyclopropyl-5-[3-[(3S)-4-(3,5-difluorophenyl)-3-methyl-piperazin-1-yl]-3-oxo-propyl]imidazolidine-2,4-dione and to pharmaceutical preparations comprising them and methods of their manufacture, as well as the use of said solid forms or preparations for the prophylaxis and/or treatment of inflammatory conditions, muscular disease, fibrotic diseases, viral infection, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis, especially osteoarthritis.

IPC Classes  ?

• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 19/00 - Drugs for skeletal disorders

Abstract

The present invention discloses compounds according to Formula (I): Wherein R1, R2, R3a, R3b, R41233, and the subscript n are as defined herein. The present invention relates to compounds inhibiting discoidin domain receptors (DDRs), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of fibrotic diseases, inflammatory diseases, respiratory diseases, autoimmune diseases, metabolic diseases, cardiovascular diseases, and/or proliferative diseases by administering a compound of the invention.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to improved methods for the use of a compound according to formula I in the treatment of fibrosis, in particular idiopathic pulmonary fibrosis (IPF), by contraindicating combined therapy with specific IPF therapeutic compounds, where the combined therapy results in a poorer adverse event profile.

IPC Classes  ?

• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, Het, X and the subscript n are as defined herein. The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, Het, X and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of endocrine, nutritional, metabolic, and/or cardiovascular diseases by administering the compound of the invention.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems

Abstract

The present invention discloses compounds according to Formula (I) wherein R1, R2, R3123 3 are as defined herein. The present invention relates to compounds inhibiting discoidin domain receptors (DDRs), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of fibrotic diseases, inflammatory diseases, respiratory diseases, autoimmune diseases, metabolic diseases, cardiovascular diseases, and/or proliferative diseases by administering a compound of the invention.

IPC Classes  ?

• C07D 217/26 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents

Abstract

EZEE)-oxime of formula (I), its pharmaceutically acceptable salts and purification.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin

Goods & Services

Pharmaceutical preparations.

Abstract

The present invention discloses compounds according to Formula I, wherein A, B, R1, R2, and Cy are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, pain, and/or abnormal angiogenesis associated diseases by administering the compounds of the invention.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• C07D 471/04 - Ortho-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 17/00 - Drugs for dermatological disorders
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention discloses compounds according to Formula (I) wherein R1, R2, and Cy are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IFNα, IL12 and/or IL23 by administering the compound of the invention.

IPC Classes  ?

• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07D 471/04 - Ortho-condensed systems
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Goods & Services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Education services, namely, organising and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals; provision of training, namely provision of training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; laboratory analysis and testing services in the field of gene expression; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of computer data banks containing information concerning gene expression and gene therapy; pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Education services, namely, organising and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals; provision of training, namely provision of training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; laboratory analysis and testing services in the field of gene expression; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of computer data banks containing information concerning gene expression and gene therapy; pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Abstract

The present invention discloses compounds according to Formula (I), wherein R1a, R1b, R1c, R2a121233, Y, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

IPC Classes  ?

• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention discloses compounds according to Formula (I), wherein R1, R2a122, Y and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

IPC Classes  ?

• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Abstract

The present invention relates to prodrug compounds and their use in the treatment of Cystic Fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

IPC Classes  ?

• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention discloses compounds according to Formula (I), wherein X, G, R1, R2a, R2b, R3, R4, and R5 are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving hepatitis B by administering the compound of the invention.

IPC Classes  ?

• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• C07D 495/04 - Ortho-condensed systems
• A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine

Goods & Services

Pharmaceutical preparations.

Abstract

The present invention discloses compounds according to Formula I: (l) Wherein R1is as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of that may be useful in the prophylaxis and/or treatment of polycystic kidney disease (PKD), by administering the compound of the invention.

IPC Classes  ?

• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Abstract

The present invention discloses compounds according to Formula (I): (I). Wherein R1, R2, R5 and Cy are as defined herein. The present invention relates to compounds, methods for the production of said compounds, pharmaceutical compositions comprising said compounds and methods for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases, pain, fibrosis and/or proliferative diseases by administering said compounds.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61P 31/18 - Antivirals for RNA viruses for HIV
• A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon

Abstract

The present invention discloses compounds according to Formula I, wherein R1, R2, and Cy are as defined herein. The present invention relates to compounds, methods for the production of said compounds, pharmaceutical compositions comprising said compounds and methods for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases, pain, fibrosis and/or proliferative diseases by administering said compounds.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole

Abstract

The present invention discloses compounds according to Formula I: Wherein R1, R2, R5 and Cy are as defined herein. The present invention relates to compounds, methods for the production of said compounds, pharmaceutical compositions comprising said compounds and methods for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases, pain, fibrosis and/or proliferative diseases by administering said compounds.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61P 31/18 - Antivirals for RNA viruses for HIV
• A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon

Goods & Services

Education services, namely, organizing and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals for the treatment of medical disorders and dissemination of materials in connection therewith; provision of training, namely, provision of training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals for the treatment of medical disorders and dissemination of materials in connection therewith Medical and scientific research services; industrial research services in the field of assay development, target discovery and validation, drug development, and medicinal chemistry; pharmaceutical and biopharmaceutical research and development services; medical and scientific research, namely, the examination and testing of genes; development, laboratory analysis, and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis, and testing of medicaments; the development of clinical assays, cellular tests, testing kits, diagnostic kits, and companion diagnostics for evaluating pharmaceutical and biopharmaceutical products of others; development of computer databases in the medical, pharmaceutical and biopharmaceutical fields; development of computer data banks containing information concerning gene expression and gene therapy; pharmaceutical drug development services Medical services; medical and pharmaceutical advisory and consultancy services; gene bank services

Goods & Services

Education services, namely, organizing and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals for the treatment of medical disorders and dissemination of materials in connection therewith; provision of training, namely, provision of training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals for the treatment of medical disorders and dissemination of materials in connection therewith Medical and scientific research services; industrial research services in the field of assay development, target discovery and validation, drug development, and medicinal chemistry; pharmaceutical and biopharmaceutical research and development services; medical and scientific research, namely, the examination and testing of genes; development, laboratory analysis, and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis, and testing of medicaments; the development of clinical assays, cellular tests, testing kits, diagnostic kits, and companion diagnostics for evaluating pharmaceutical and biopharmaceutical products of others; development of computer databases in the medical, pharmaceutical and biopharmaceutical fields; development of computer data banks containing information concerning gene expression and gene therapy; pharmaceutical drug development services Medical services; medical and pharmaceutical advisory and consultancy services; gene bank services

Abstract

The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, Het, X and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of endocrine, nutritional, metabolic, and/or cardiovascular diseases by administering the compound of the invention.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 5/00 - Drugs for disorders of the endocrine system
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Abstract

The invention discloses compounds of Formula (I), 4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

IPC Classes  ?

• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07C 311/45 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
• C07D 213/30 - Oxygen atoms
• C07D 213/64 - One oxygen atom attached in position 2 or 6
• C07D 213/71 - Sulfur atoms to which a second hetero atom is attached
• C07D 215/36 - Sulfur atoms
• C07D 231/56 - BenzopyrazolesHydrogenated benzopyrazoles
• C07D 235/28 - Sulfur atoms
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention relates to pyrrolopyrimidine compounds according to Formula I and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. In a particular aspect, the present compounds are ASK inhibitors, particularly ASK1 inhibitors. The present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, the use of the compounds in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 11/00 - Drugs for disorders of the respiratory system
• C07D 471/04 - Ortho-condensed systems

Goods & Services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Education services, namely, organising and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals; provision of training, namely provision of training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; laboratory analysis and testing services in the field of gene expression; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of computerdatabanks containing information concerning gene expression and gene therapy; pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Goods & Services

Pharmaceutical substances and preparations for human use; biopharmaceutical substances and preparations for human use. Education services, namely, organising and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals; provision of training, namely provision of training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals. Medical, scientific and industrial research services; pharmaceutical and biopharmaceutical research and development services; laboratory analysis and testing services in the field of gene expression; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis and testing of medicaments; the development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field and development of computerdatabanks containing information concerning gene expression and gene therapy; pharmaceutical drug development services. Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals for others.

Abstract

The present invention relates to improved methods of administering compound 1 therapy, involving increased effectiveness of compound 1 by avoiding or contraindicating combined CYP3A4/P-gp inducers, e.g. rifampicin.

IPC Classes  ?

• A61P 11/00 - Drugs for disorders of the respiratory system
• A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine

Abstract

The present disclosure describes high concentration liquid formulations of a pharmaceutically active antigen binding protein, for example a monoclonal antibody. Such formulations comprise, in addition to the antigen binding protein, at least 80mM of a buffering agent and at least 80mM of a stabilizer. In addition, the present disclosure is related to pharmaceutical formulations of an anti-IL-17C antibody and provides methods of making and methods of using such formulations.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention discloses compounds according to Formula I: wherein R1, R2a, X, Y, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

IPC Classes  ?

• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• C07D 471/04 - Ortho-condensed systems
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention relates to compound according to Formula I: or a pharmaceutically acceptable salt thereof, or a solvate or the salt of a solvate thereof, pharmaceutical compositions comprising the same, and methods of treatment using the same, for use in the treatment of psoriatic arthritis, by administering the compound according to Formula I.

IPC Classes  ?

• A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
• A61P 17/06 - Antipsoriatics
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

The present invention provides for compounds of formula (I) 6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention discloses compounds of Formula (I) wherein R1, R2, R3, R3A, R4, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

IPC Classes  ?

• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 407/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The present invention relates to the use of an antibody or antibody fragment specific for IL-17C in the prophylaxis and/or treatment of autoimmune skin diseases. In one embodiment, the antibody or antibody fragment specific for IL-17C comprises a HCDR1 region of amino acid sequence SEQ ID NO: 7, a HCDR2 region of amino acid sequence SEQ ID NO: 8, a HCDR3 region of amino acid sequence of SEQ ID NO: 9, a LCDR1 region of amino acid sequence SEQ ID NO: 13, a LCDR2 region of amino acid sequence of SEQ ID NO: 14 and a LCDR3 region of amino acid sequence SEQ ID NO: 15. In another embodiment, the antibody or antibody fragment specific for IL-17C comprises a variable heavy chain of SEQ ID NO: 17 and a variable light chain of SEQ ID NO: 16. In some embodiments the autoimmune skin disease is selected from pemphigus vulgaris, bullous pemphigoid, vasculitis, pyoderma gangrenosum and Sweet's disease.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Abstract

The present invention discloses compounds according to Formula (I), wherein R1, R2a, R2b, R3, R4, and R5 are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving hepatitis B by administering the compound of the invention.

IPC Classes  ?

• C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
• A61P 31/20 - Antivirals for DNA viruses
• A61P 31/12 - Antivirals
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin

Abstract

The present invention discloses compounds according to Formula (I): wherein R1, R2, R3a, R3b1233, and Z are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of TNFα, interferons, IL-6, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.

IPC Classes  ?

• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 471/04 - Ortho-condensed systems
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention relates to compounds useful in the prophylaxis and/or treatment of one or more fibrotic diseases. In particular, the compounds of the invention antagonize GPR84, a G-protein-coupled receptor. The present invention also provides pharmaceutical compositions comprising the compounds for use and methods for the prophylaxis and/or treatment of one or more fibrotic diseases by administering said compound.

IPC Classes  ?

• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention discloses compounds according to Formula I: (Formula I) Wherein R111, R222, R3, Cy, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IFNα, IL12 and/or IL23 by administering the compound of the invention.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings

Abstract

The present invention discloses compounds according to Formula I: (Formula I) Wherein $R^1$, $L_1$, $R^2$, $L_2$, $R^3$, Cy, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, au- toimmune diseases, proliferative diseases, transplantation rejection, diseases involving impair- ment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IFNα, IL12 and/or IL23 by administering the compound of the invention.

IPC Classes  ?

• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• C07D 471/04 - Ortho-condensed systems